TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15716208

Group type: EXPERIMENTAL
Intervention: Surgery (decompression of the pudendal nerve)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (non-surgical treatment)
Number of subjects: 32
Study: 12429622

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m2 followed by paclitaxel 200 mg/m2 (1- or 3-hour infusion) for six to seven cycles.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Doxorubicin dose > 360 mg/m2
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Doxorubicin dose 420 mg/m2
Number of subjects: 82

Group type: COMPARATOR
Intervention: Doxorubicin dose < or = 360 mg/m2
Number of subjects: 82
Study: 10430734

Group type: EXPERIMENTAL
Intervention: Low and high doses of budesonide with and without formoterol
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids prescribed for severe exacerbations
Number of subjects: 425

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 425
Study: 7748095

Group type: EXPERIMENTAL
Intervention: Intra‐operative management with endotracheal intubation, general anesthesia, nasogastric and urinary bladder catheters, position changes, rectal manometer, respiratory pressure module
Number of subjects: 26

Group type: COMPARATOR
Intervention: Measurement techniques (bladder, rectal, gastric)
Number of subjects: 26
Study: 3579494

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scopolamine 0.1 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scopolamine 0.5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31808183

Group type: EXPERIMENTAL
Intervention: Treatment protocol from 2008-2011 (all foals with pulmonary abscesses treated)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Treatment protocol from 2012-2016 (only foals with larger lesions treated)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Treatment protocol from 2008-2011
Number of subjects: 330

Group type: COMPARATOR
Intervention: Treatment protocol from 2012-2016
Number of subjects: 330
Study: 29288881

Group type: EXPERIMENTAL
Intervention: EHR phenotype screening method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily screening including confirmatory chart reviews
Number of subjects: 0
Study: 28747169

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including a two-hour educational session, online video, decision tool, and information booklet.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 0
Study: 25703382

Group type: EXPERIMENTAL
Intervention: Discussion group on 'dealing with disobedience'
Number of subjects: 108

Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 108
Study: 23312489

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training for 11 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study: 20679559

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 307

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 307
Study: 17997269

Group type: EXPERIMENTAL
Intervention: Direct bypass
Number of subjects: 143

Group type: COMPARATOR
Intervention: Crossover bypass
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 143
Study: 21776461

Group type: EXPERIMENTAL
Intervention: Nutritional advice adapted to a Mediterranean diet (MD)
Number of subjects: 40
Study: 16174597

Group type: EXPERIMENTAL
Intervention: Cefepime (Maxipime) at 50 mg/kg intravenously twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sulbactam/Cefoperazone (Sulperazone) at 50-100 mg/kg intravenously twice daily
Number of subjects: 100
Study: 12045314

Group type: EXPERIMENTAL
Intervention: Psychoeducational multiple-family group treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 106
Study: 9179369

Group type: EXPERIMENTAL
Intervention: Mistletoe lectin-I treatment
Number of subjects: 0
Study: 8186809

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 3129318

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC), 25 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo, 1 tablet/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 23
Study: 11120961

Group type: EXPERIMENTAL
Intervention: Telithromycin 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telithromycin 1600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31476881

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) treatment
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: IABP treatment
Number of subjects: 281
Study: 29559225

Group type: EXPERIMENTAL
Intervention: Flashing warning light during ERCP
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no flashing warning light)
Number of subjects: 200
Study: 26843544

Group type: EXPERIMENTAL
Intervention: PIPJ resection
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PIPJ fusion
Number of subjects: 55

Group type: COMPARATOR
Intervention: PIPJ resection and PIPJ fusion
Number of subjects: 55
Study: 25102384

Group type: EXPERIMENTAL
Intervention: Activity-based therapy (ABT) 9h/wk for 24 weeks
Number of subjects: 48
Study: 23013404

Group type: EXPERIMENTAL
Intervention: Coping-Together intervention (self-directed coping skills intervention including four booklets, a DVD, and a relaxation audio CD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Minimal ethical care condition (information booklets from Cancer Council New South Wales and a brochure for the Cancer Council Helpline)
Number of subjects: 70
Study: 20357161

Group type: EXPERIMENTAL
Intervention: Conventional cooling methods (therapeutic hypothermia)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Standard post-resuscitation care
Number of subjects: 481
Study: 17653880

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 508

Group type: COMPARATOR
Intervention: Serial antenatal monitoring
Number of subjects: 508
Study: 15705638

Group type: EXPERIMENTAL
Intervention: Local practice guidelines implemented in hospital B (low grade intervention)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Guidelines reinforced by a clinical pharmacist in hospital C (high grade intervention)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: No intervention in hospital A (control)
Number of subjects: 1200
Study: 12011136

Group type: EXPERIMENTAL
Intervention: Adjuvant oophorectomy and tamoxifen (20 mg orally every day for 5 years)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 709
Study: 10210974

Group type: EXPERIMENTAL
Intervention: HAART (combination of zidovudine, lamivudine, and saquinavir)
Number of subjects: 163
Study: 7609287

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition support (feeding tube providing 35 nonprotein kcal/kg of ideal body weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active Crohn's disease patients (before intervention)
Number of subjects: 30
Study: 2575453

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene napsylate with acetaminophen (DPN-A)
Number of subjects: 26
Study: 57506

Group type: EXPERIMENTAL
Intervention: bromocriptine (CB 154)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: bromocriptine 2-5 mg twice daily from the 10th day of the menstrual cycle for 1-11 months
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: bromocriptine 2-5 mg twice daily for 186 cycles
Number of subjects: 96

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 96
Study: 31557329

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist/Treatment as Usual (WL/TAU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 28562434

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy (5-FU-ALA-PDT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 5-Aminolevulinic Acid Photodynamic Therapy (ALA-PDT)
Number of subjects: 17
Study: 25239030

Group type: EXPERIMENTAL
Intervention: US + LLLT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TE + US + LLLT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 23784895

Group type: EXPERIMENTAL
Intervention: 400 mg herbal capsules twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: 400 mg placebo capsules twice daily
Number of subjects: 60
Study: 21554496

Group type: EXPERIMENTAL
Intervention: Double‐filtration plasmapheresis (DFP)
Number of subjects: 20
Study: 19386210

Group type: EXPERIMENTAL
Intervention: Various treatments used for EM (specific treatments not detailed in the abstract)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 12
Study: 16749914

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 32
Study: 12819167

Group type: EXPERIMENTAL
Intervention: Vitamin E 50 IU/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10671819

Group type: COMPARATOR
Intervention: Normal pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-eclamptic pregnancies
Number of subjects: 0
Study: 8872421

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.) alone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: GHRH combined with pyridostigmine (PD) (60 and 120 mg orally at -60 min)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: GHRH combined with PD
Number of subjects: 57

Group type: COMPARATOR
Intervention: GHRH alone or combined with PD in DS adults
Number of subjects: 57
Study: 1804283

Group type: EXPERIMENTAL
Intervention: 150 IU kallikrein t.i.d. for eight days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6519623

Group type: EXPERIMENTAL
Intervention: Peptide diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal diet (Control)
Number of subjects: 0
Study: 31605983

Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neuroscience group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Total group
Number of subjects: 120
Study: 30278568

Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated patch (Lignopad)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo plasters
Number of subjects: 28
Study: 27075659

Group type: EXPERIMENTAL
Intervention: UCB-MNCs (4-μl injections, 1.6 million cells)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UCB-MNCs (8-μl injections, 3.2 million cells)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UCB-MNCs (16-μl injections, 6.4 million cells)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UCB-MNCs (6.4 million cells) plus 30 mg/kg methylprednisolone (MP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UCB-MNCs (6.4 million cells) plus MP and a 6-week course of oral lithium carbonate (750 mg/day)
Number of subjects: 28
Study: 24892114

Group type: EXPERIMENTAL
Intervention: 1-stage lateral window sinus lift with simultaneous implant placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2-stage procedure with implant placement delayed by 4 months
Number of subjects: 60
Study: 22132792

Group type: COMPARATOR
Intervention: Cold water immersion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ice slurry ingestion
Number of subjects: 8
Study: 20645948

Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Number of subjects: 152

Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 152
Study: 17653588

Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thyroidectomy (MIVAT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Minimally invasive open thyroidectomy using the Sofferman technique
Number of subjects: 68
Study: 15756408

Group type: EXPERIMENTAL
Intervention: Transnasal transsphenoidal endoscopic approach
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (microscopic sublabial transseptal transsphenoidal approach)
Number of subjects: 10
Study: 11939990

Group type: EXPERIMENTAL
Intervention: Tracheal intubation via direct laryngoscopy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tracheal intubation via an intubating laryngeal mask airway with immediate removal
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tracheal intubation via an intubating laryngeal mask airway with delayed removal
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 61
Study: 9565250

Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline treatment (1.5 mg/kg/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study: 7800378

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (30 mg of beta-carotene, 1000 mg of ascorbic acid, and 800 IU of alpha-tocopherol per day for 9 months)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 79
Study: 3377462

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg orally twice daily for 4 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theophylline (200 mg of aminophylline three times daily for 4 days)
Number of subjects: 10
Study: 31730832

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) administered before and after treatment of acute exacerbations
Number of subjects: 0
Study: 30762744

Group type: EXPERIMENTAL
Intervention: Holistic care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 100
Study: 28940638

Group type: EXPERIMENTAL
Intervention: l-citrulline (6 g day-1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo (maltodextrin)
Number of subjects: 25
Study: 26342424

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccination
Number of subjects: 15459

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccination with booster dose
Number of subjects: 15459
Study: 23610477

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lecture followed by simulation
Number of subjects: 0
Study: 21777095

Group type: EXPERIMENTAL
Intervention: Oxalic acid (BisBlock) before resin‐based composite (RBC) restorations (n=52)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Distilled water before RBC restorations (n=51)
Number of subjects: 103
Study: 18833582

Group type: EXPERIMENTAL
Intervention: General preoccupation prime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standardized preoccupation prime
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control prime
Number of subjects: 60
Study: 17198101

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol and remifentanil; maintained constant rates to achieve BIS levels of 40-60 during the procedure
Number of subjects: 36
Study: 15087795

Group type: COMPARATOR
Intervention: Rigid instrumentation (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Semirigid instrumentation (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dynamic instrumentation (Group C)
Number of subjects: 45
Study: 11292410

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 15 to 20 mg of crystalline triamcinolone acetonide at the end of surgery
Number of subjects: 29
Study: 9380943

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5 mg) via active matrix
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg) via active matrix
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5 mg) via polyptychial matrix
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg) via polyptychial matrix
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 10
Study: 8174303

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3069548

Group type: EXPERIMENTAL
Intervention: Gastric ulcer patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Duodenal ulcer patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study: 2119183

Group type: EXPERIMENTAL
Intervention: Consistent wound care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Carefully controlled nutritional support
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both consistent wound care and carefully controlled nutritional support
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard hospital treatment
Number of subjects: 80
Study: 4758446

Group type: EXPERIMENTAL
Intervention: Frusemide 2000 mg daily
Number of subjects: 105
Study: 31043522

Group type: EXPERIMENTAL
Intervention: Intranasal arginine vasopressin (AVP) treatment (24 IU for ages 6-9.5 years; 32 IU for ages 9.6-12.9 years)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal arginine vasopressin (AVP) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 27683405

Group type: EXPERIMENTAL
Intervention: Intracoronary sodium nitrite
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25372313

Group type: EXPERIMENTAL
Intervention: 810-nm pulsed diode laser treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall score combining erythema and roughness/bumpiness for treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Overall score combining erythema and roughness/bumpiness for control
Number of subjects: 18
Study: 23834688

Group type: EXPERIMENTAL
Intervention: Carvedilol (up to 0.8 mg/kg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no carvedilol)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 21360353

Group type: EXPERIMENTAL
Intervention: Group CBT (Cognitive Behavioral Therapy)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 12
Study: 19515179

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg b.i.d.)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 576
Study: 17274272

Group type: EXPERIMENTAL
Intervention: Water (group GW, n=12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Electrolytic carbohydrate solution (group GP, n=14)
Number of subjects: 26
Study: 15025744

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no perhexiline)
Number of subjects: 32
Study: 11424515

Group type: EXPERIMENTAL
Intervention: Dietary manipulation focusing on non-starch polysaccharides (NSPs), mono and disaccharide sensitivity, and food intolerance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for dietetic practice in IBS
Number of subjects: 0
Study: 9549742

Group type: EXPERIMENTAL
Intervention: Clonidine 1 microgram.kg‐1 with 0.25% bupivacaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1 ml normal saline (placebo)
Number of subjects: 24
Study: 7523785

Group type: EXPERIMENTAL
Intervention: Abanoquil (UK 52,046)
Number of subjects: 27
Study: 3060626

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (CPDX‐PR) 400 mg daily for 7 days
Number of subjects: 243

Group type: COMPARATOR
Intervention: Cefaclor (CCL) 750 mg daily for 7 days
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (CPDX‐PR)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Cefaclor (CCL)
Number of subjects: 243
Study: 28910139

Group type: EXPERIMENTAL
Intervention: Family-based cognitive-behavioral therapy (CBT), 10 sessions
Number of subjects: 142
Study: 25940277

Group type: EXPERIMENTAL
Intervention: Usual care plus a decision aid presenting risks and benefits of different treatments (surgery and radiotherapy)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Usual care plus a decision aid
Number of subjects: 240
Study: 24467988

Group type: EXPERIMENTAL
Intervention: Clinical score (FeverPAIN)
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: RAPD (Rapid Antigen Detection Test)
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Delayed antibiotics (control group)
Number of subjects: 1760
Study: 22075119

Group type: EXPERIMENTAL
Intervention: Student-focused feedback instructional session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Compliments (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback (Instructional)
Number of subjects: 0
Study: 19801528

Group type: EXPERIMENTAL
Intervention: Persuasive communication goal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accurate communication goal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asking for an opinion
Number of subjects: 0

Group type: COMPARATOR
Intervention: No communication goal
Number of subjects: 0
Study: 17563145

Group type: EXPERIMENTAL
Intervention: Same context as extinction
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Different context
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Different context containing an extinction cue
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Different context with cue plus manipulation to increase salience
Number of subjects: 143
Study: 15663405

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 mug oral + 400 mug intravaginal, repeated every 6 hours for a maximum of five doses)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no previous caesarean section)
Number of subjects: 324